Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Hagens Berman Sobol Shapiro LLP and Scott+Scott Attorneys at Law LLP Announce a Class Action for All Vaxart Shareholders that May Include You, Even if You Participated in the Previous Partial Settlement with Vaxart

NEW YORK--(BUSINESS WIRE)--Hagens Berman Sobol Shapiro LLP & Scott+Scott Attorneys at Law LLP: UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA In re VAXART, INC. SECURITIES LITIGATION This Document Relates to: ALL ACTIONS Master Case No. 3:20-cv-05949-VC SUPPLEMENTAL SUMMARY NOTICE OF CLASS CERTIFICATION THIS SUPPLEMENTAL NOTICE PROVIDES ONLY LIMITED INFORMATION ABOUT THE CASE PLEASE VISIT WWW.VAXARTSECURITIESLITIGATION.COM FOR MORE INFORMATION The Court has certified this laws.

Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026

SOUTH SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart or “the Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that it will participate in the Global BioInnovation Forum, a virtual gathering of senior leaders building and scaling next-generation life science and health innovation companies.

Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; r eiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 million Board of Directors authorizes new $100 million share repurchase program  Positive topline Phase 1/2 shingles vaccine trial data presented in late-breaker session at IDWeek Enters exclusive license agreement for Vaxart's novel oral COVID-19 vaccine program, expanding pipeline opportunities Conference call today at 4:30 p.m. ET/1:30 p.m.

Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

Collaboration positioned to leverage Vaxart's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered COVID-19 vaccine options Vaxart to continue leading and funding development through Phase 2b completion and End of Phase 2 meeting with FDA ; Dynavax to receive exclusive, worldwide license and right to assume responsibility for continued clinical development and commercialization following Phase 2b clinical development Vaxart will receive a $25 million upfront payment and a $5 million equity investment from Dynavax, along with additional potential milestone-based payments and royalties contingent on Dynavax advancing the program post-Phase 2b data readout EMERYVILLE, Calif. and SOUTH SAN FRANCISCO, Calif.